.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Expert Views on Therapy for Ovarian, Fallopian, and Peritoneal Cancers

EP. 1: Classification of Ovarian Cancers

January 20th 2017

EP. 2: BRCA Testing for Ovarian Cancer

January 20th 2017

EP. 3: When to Refer to Genetic Counseling

January 20th 2017

EP. 4: Surgical Management of Advanced Ovarian Cancer

January 20th 2017

EP. 5: Intravenous vs Intraperitoneal Chemotherapy for Ovarian Cancer

January 20th 2017

EP. 6: Dose-Dense Chemotherapy for Ovarian Cancer; Adding Bevacizumab

January 20th 2017

EP. 7: Recurrent Ovarian Cancer; Considerations Beyond the Platinum-Free Interval

January 20th 2017

EP. 8: Bevacizumab for Recurrent Ovarian Cancer

January 20th 2017

EP. 9: PARP Inhibitors for Ovarian Cancer: Use of Olaparib

January 20th 2017

EP. 10: Rucaparib for Ovarian Cancer

January 20th 2017

EP. 11: Niraparib Maintenance Therapy for Ovarian Cancer

January 20th 2017

EP. 12: Sequencing Therapies for Ovarian Cancer

January 20th 2017

EP. 13: Differences Among PARP Inhibitors in Ovarian Cancer

January 20th 2017

EP. 14: Ongoing PARP Inhibitor Research in Ovarian Cancer

January 20th 2017

EP. 15: Future Directions for Treating Advanced Ovarian Cancers

January 20th 2017